Ergoteles’s Ascendis Pharma A/S ASND Stock Holding History

Ergoteles’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,511	Closed	-$1.21M	–	92
2023 Q2	$1.21M	Buy	13,511 +6,749	+100%	+$587K	0.06%	416
2023 Q1	$725K	Buy	6,762 +2,095	+45%	+$240K	0.03%	612
2022 Q4	$570K	Buy	4,667 +2,232	+92%	+$259K	0.02%	649
2022 Q3	$251K	Buy	2,435 +194	+9%	+$18.4K	0.01%	1070
2022 Q2	$208K	Buy	+2,241	New	+$211K	0.01%	1303
2022 Q1	–	Sell	-13,165	Closed	-$1.77M	–	1202
2021 Q4	$1.77M	Buy	+13,165	New	+$1.96M	0.07%	276
2021 Q2	–	Sell	-18,547	Closed	-$2.39M	–	1483
2021 Q1	$2.39M	Buy	+18,547	New	+$2.82M	0.07%	256

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ergoteles's ASND Position: Q3 2023 in Review

Ergoteles sold out of Ascendis Pharma A/S (ASND) in Q3 2023, closing a stake of 13,511 shares — an estimated $1.21M sold.

Ergoteles first reported a position in ASND in Q1 2021 and held it in 7 quarters. The position peaked at $2.39M in Q1 2021. 160 funds tracked by Wall St. Rank hold ASND as of Q3 2023.

Ergoteles reported no remaining Ascendis Pharma A/S position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 13,511 Ascendis Pharma A/S shares in Q3 2023, an estimated $1.21M.
Ergoteles first reported a position in Ascendis Pharma A/S in Q1 2021 and held it in 7 quarters.
Ergoteles's Ascendis Pharma A/S position peaked at $2.39M in Q1 2021.
160 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.